Open Access

METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression

  • Authors:
    • Yongxi Zhang
    • Shuyuan Liu
    • Tiesuo Zhao
    • Chengxue Dang
  • View Affiliations

  • Published online on: June 15, 2021     https://doi.org/10.3892/or.2021.8114
  • Article Number: 163
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Methyltransferase‑like 3 (METTL3) is an RNA methyltransferase that mediates modification of N6‑methyladenosine (m6A), which serves as an oncogene in various types of cancer. The role of m6A modification in the onset and progression of cancer has attracted growing attention. However, the functional and regulatory mechanisms of METTL3 in non‑small cell lung cancer (NSCLC) progression are still poorly understood. In the present study, METTL3 expression in NSCLC tissue was analyzed using the Gene Expression Profiling Interactive Analysis database. Western blotting and reverse transcription‑quantitative PCR were performed to evaluate the expression of METTL3 in NSCLC tissue and cell lines. Here, knockdown and overexpression of METTL3 notably decreased NSCLC cell viability, apoptosis and migration in vitro and, as well as tumorigenicity in vivo. Expression of METTL3 was upregulated in NSCLC tissue. METTL3 overexpression promoted cell viability and migration in NSCLC, while knockdown of METTL3 yielded the opposite result in vivo and in vitro. METTL3 increased Bcl‑2 translation via m6A modification, which increased viability and enhanced migration of NSCLC cells. METTL3 served as an oncogene in NSCLC via METTL3‑mediated Bcl‑2 mRNA m6A modification, which indicated that targeting METTL3 may be an effective therapeutic strategy for clinical management of NSCLC.
View Figures
View References

Related Articles

Journal Cover

August-2021
Volume 46 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Y, Liu S, Zhao T and Dang C: METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression. Oncol Rep 46: 163, 2021
APA
Zhang, Y., Liu, S., Zhao, T., & Dang, C. (2021). METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression. Oncology Reports, 46, 163. https://doi.org/10.3892/or.2021.8114
MLA
Zhang, Y., Liu, S., Zhao, T., Dang, C."METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression". Oncology Reports 46.2 (2021): 163.
Chicago
Zhang, Y., Liu, S., Zhao, T., Dang, C."METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression". Oncology Reports 46, no. 2 (2021): 163. https://doi.org/10.3892/or.2021.8114